DE19933288A1 - Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung - Google Patents

Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung

Info

Publication number
DE19933288A1
DE19933288A1 DE19933288A DE19933288A DE19933288A1 DE 19933288 A1 DE19933288 A1 DE 19933288A1 DE 19933288 A DE19933288 A DE 19933288A DE 19933288 A DE19933288 A DE 19933288A DE 19933288 A1 DE19933288 A1 DE 19933288A1
Authority
DE
Germany
Prior art keywords
structural protein
mutation
protein according
aav
structural
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19933288A
Other languages
German (de)
English (en)
Inventor
Michael Hallek
Anne Girod
Martin Ried
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medigene AG
Original Assignee
Medigene AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene AG filed Critical Medigene AG
Priority to DE19933288A priority Critical patent/DE19933288A1/de
Priority to EP08022398A priority patent/EP2060634A1/de
Priority to AU66931/00A priority patent/AU781397B2/en
Priority to US10/031,313 priority patent/US7252997B1/en
Priority to JP2001511200A priority patent/JP4842471B2/ja
Priority to EP00954493A priority patent/EP1198581B1/de
Priority to ES00954493T priority patent/ES2320970T3/es
Priority to AT00954493T priority patent/ATE420192T1/de
Priority to PCT/EP2000/006692 priority patent/WO2001005990A1/de
Priority to DE50015518T priority patent/DE50015518D1/de
Priority to CA2379220A priority patent/CA2379220C/en
Publication of DE19933288A1 publication Critical patent/DE19933288A1/de
Priority to US11/880,592 priority patent/US7556965B2/en
Priority to US12/484,694 priority patent/US7968340B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE19933288A 1999-07-15 1999-07-15 Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung Ceased DE19933288A1 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DE19933288A DE19933288A1 (de) 1999-07-15 1999-07-15 Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
AT00954493T ATE420192T1 (de) 1999-07-15 2000-07-13 Verfahren zur verringerung der antigenität des adeno-assoziierten virus strukturproteins
PCT/EP2000/006692 WO2001005990A1 (de) 1999-07-15 2000-07-13 Strukturprotein von adeno-assoziiertem virus mit veränderter antigenität, seine herstellung und verwendung
US10/031,313 US7252997B1 (en) 1999-07-15 2000-07-13 Structural protein of adeno-associated virus with modified antigenicity, its production and its use
JP2001511200A JP4842471B2 (ja) 1999-07-15 2000-07-13 修飾された抗原性を有するアデノ随伴ウイルスの構造タンパク質と、その製造及び使用
EP00954493A EP1198581B1 (de) 1999-07-15 2000-07-13 vERFAHREN ZUR VERRINGERUNG DER ANTIGENITÄT DES ADENO-ASSOZIIERTEN VIRUS STRUKTURPROTEINS
ES00954493T ES2320970T3 (es) 1999-07-15 2000-07-13 Procedimiento para disminuir la antigenicidad de la proteina estructural de virus adeno-asociado.
EP08022398A EP2060634A1 (de) 1999-07-15 2000-07-13 Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
AU66931/00A AU781397B2 (en) 1999-07-15 2000-07-13 Structural protein of adeno-associated virus with modified antigenicity, its production and its use
DE50015518T DE50015518D1 (de) 1999-07-15 2000-07-13 vERFAHREN ZUR VERRINGERUNG DER ANTIGENITÄT DES ADENO-ASSOZIIERTEN VIRUS STRUKTURPROTEINS
CA2379220A CA2379220C (en) 1999-07-15 2000-07-13 Structural protein of adeno-associated virus with modified antigenicity, its production and its use
US11/880,592 US7556965B2 (en) 1999-07-15 2007-07-23 Structural protein of adeno-associated virus with modified antigenicity, its production and its use
US12/484,694 US7968340B2 (en) 1999-07-15 2009-06-15 Structural protein of adeno-associated virus with modified antigenicity, its production and its use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19933288A DE19933288A1 (de) 1999-07-15 1999-07-15 Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
DE19933288A1 true DE19933288A1 (de) 2001-01-18

Family

ID=7914953

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19933288A Ceased DE19933288A1 (de) 1999-07-15 1999-07-15 Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
DE50015518T Expired - Lifetime DE50015518D1 (de) 1999-07-15 2000-07-13 vERFAHREN ZUR VERRINGERUNG DER ANTIGENITÄT DES ADENO-ASSOZIIERTEN VIRUS STRUKTURPROTEINS

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50015518T Expired - Lifetime DE50015518D1 (de) 1999-07-15 2000-07-13 vERFAHREN ZUR VERRINGERUNG DER ANTIGENITÄT DES ADENO-ASSOZIIERTEN VIRUS STRUKTURPROTEINS

Country Status (9)

Country Link
US (3) US7252997B1 (cg-RX-API-DMAC7.html)
EP (2) EP1198581B1 (cg-RX-API-DMAC7.html)
JP (1) JP4842471B2 (cg-RX-API-DMAC7.html)
AT (1) ATE420192T1 (cg-RX-API-DMAC7.html)
AU (1) AU781397B2 (cg-RX-API-DMAC7.html)
CA (1) CA2379220C (cg-RX-API-DMAC7.html)
DE (2) DE19933288A1 (cg-RX-API-DMAC7.html)
ES (1) ES2320970T3 (cg-RX-API-DMAC7.html)
WO (1) WO2001005990A1 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
DE19933288A1 (de) * 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP1828390B1 (en) * 2004-12-15 2012-06-13 The University Of North Carolina At Chapel Hill Chimeric vectors
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
EP2158211B1 (en) 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
CA2754335C (en) 2009-03-04 2019-12-24 Medigene Ag Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
DK3693025T3 (da) 2011-04-22 2022-01-10 Univ California Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf
US9821043B2 (en) 2011-09-15 2017-11-21 Medigene Ag Anti-HER2 vaccine based upon AAV derived multimeric structures
EP2764119A2 (en) 2011-10-05 2014-08-13 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
US11136557B2 (en) 2013-05-31 2021-10-05 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
ES2822551T3 (es) 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
FI3265178T3 (fi) 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
JP6836999B2 (ja) 2015-03-24 2021-03-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California アデノ随伴ウイルス変異体及びその使用方法
US10081659B2 (en) 2015-04-06 2018-09-25 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Adeno-associated vectors for enhanced transduction and reduced immunogenicity
IL314171A (en) * 2015-09-28 2024-09-01 Univ Florida Methods and compositions for antibody-evading virus vectors
AU2017248830B2 (en) 2016-04-15 2023-03-09 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CN109640949B (zh) 2016-07-29 2022-11-25 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体和其使用方法
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
EP3583220A4 (en) * 2017-02-15 2021-07-07 The University of North Carolina at Chapel Hill PROCEDURES AND COMPOSITIONS FOR GENERAL TRANSFER IN THE VASCULAR SYSTEM
MX2019010887A (es) 2017-03-16 2019-10-15 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de cb80 variante y usos de estas.
FI3596116T3 (fi) 2017-03-16 2023-11-09 Alpine Immune Sciences Inc Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Pd−l2バリアント免疫調節タンパク質及びその使用
KR20250023600A (ko) 2017-06-30 2025-02-18 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 변이체 캡시드를 보유한 아데노-부속 바이러스 비리온 및 이의 사용 방법
MX2020001997A (es) 2017-08-28 2020-07-20 Univ California Variantes de capside de virus adenoasociado y metodos de uso de estas.
JP7282760B2 (ja) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
CA3095179A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
KR102662837B1 (ko) 2018-06-04 2024-05-03 카리디 바이오테라퓨틱스, 인크. 바이러스 치료법의 강화를 위한 세포-기반 비히클
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020047161A2 (en) 2018-08-28 2020-03-05 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3116192C (en) 2018-11-06 2025-09-23 Calidi Biotherapeutics (Nevada), Inc. IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
CN113727998A (zh) 2018-11-30 2021-11-30 高山免疫科学股份有限公司 Cd86变体免疫调节蛋白及其用途
KR20220004959A (ko) 2019-02-27 2022-01-12 액팀 테라퓨틱스, 인코퍼레이티드 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
CN113727992A (zh) 2019-03-21 2021-11-30 斯特里迪比奥公司 重组腺相关病毒载体
CN114787180A (zh) 2019-10-17 2022-07-22 斯特里迪比奥公司 用于治疗c型尼曼-匹克病的腺相关病毒载体
MX2022004353A (es) 2019-10-17 2022-07-19 Casete de transferencia de aav.
KR20230088306A (ko) 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 자연 살해(nk) 세포 조성물 및 이를 생성하는 방법
JP2023542614A (ja) 2020-08-19 2023-10-11 サレプタ セラピューティクス, インコーポレイテッド レット症候群の治療のためのアデノ随伴ウイルスベクター
AU2021410043A1 (en) * 2020-12-23 2023-06-22 Synteny Therapeutics, Inc. Protoparvovirus and tetraparvovirus compositions and methods for gene therapy
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
US12383615B2 (en) * 2023-03-23 2025-08-12 Carbon Biosciences, Inc. Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023867A1 (fr) * 1994-03-03 1995-09-08 Rhone-Poulenc Rorer S.A. Adenovirus recombinants integratifs, leur preparation et leur utilisation therapeutique

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507383A (ja) 1991-01-25 1994-08-25 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ラミニンのa鎖のドメイン6のポリペプチド
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびaavの精製
WO1997038723A1 (en) * 1996-04-16 1997-10-23 Immusol Incorporated Targeted viral vectors
US20010031463A1 (en) 1997-09-02 2001-10-18 Jurgen Kleinschmidt Method for purifying and concentrating AAV-2 and antigen portions thereof
DE19827457C1 (de) * 1998-06-19 2000-03-02 Medigene Ag Strukturprotein von AAV, seine Herstellung und Verwendung
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
DE19933288A1 (de) * 1999-07-15 2001-01-18 Medigene Ag Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
WO2002053703A2 (en) 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023867A1 (fr) * 1994-03-03 1995-09-08 Rhone-Poulenc Rorer S.A. Adenovirus recombinants integratifs, leur preparation et leur utilisation therapeutique

Also Published As

Publication number Publication date
ATE420192T1 (de) 2009-01-15
US7556965B2 (en) 2009-07-07
DE50015518D1 (de) 2009-02-26
US7252997B1 (en) 2007-08-07
EP2060634A1 (de) 2009-05-20
US20090253897A1 (en) 2009-10-08
EP1198581A1 (de) 2002-04-24
US20080064081A1 (en) 2008-03-13
AU6693100A (en) 2001-02-05
US7968340B2 (en) 2011-06-28
ES2320970T3 (es) 2009-06-01
WO2001005990A1 (de) 2001-01-25
CA2379220C (en) 2012-04-03
JP4842471B2 (ja) 2011-12-21
JP2003505032A (ja) 2003-02-12
EP1198581B1 (de) 2009-01-07
CA2379220A1 (en) 2001-01-25
AU781397B2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
EP1198581B1 (de) vERFAHREN ZUR VERRINGERUNG DER ANTIGENITÄT DES ADENO-ASSOZIIERTEN VIRUS STRUKTURPROTEINS
EP1198580B1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
EP1783225B1 (de) Strukturprotein von AAV, seine Herstellung und Verwendung
DE69433592T2 (de) Die erzielung hoher titer des rekombinanten aav-vektors
DE60117550T2 (de) Doppelsträngige parvovirus-vektoren
DE69936104T2 (de) Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
US7105345B2 (en) Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
DE69738351T2 (de) Verfaheren zur durch rekombinante adeno-assoziierte virus-gerichtete gentherapie
DE10066104A1 (de) Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung
JP2018121653A (ja) ウイルスベクター精製における拡張可能な製造プラットフォームおよび遺伝子治療における使用のための高純度ウイルスベクター
EP1015619A1 (en) Methods and cell line useful for production of recombinant adeno-associated viruses
DE69930625T2 (de) Rekombinante aav-vektoren für die gentherapie von hämophilie a
EP1412510B1 (de) Aav-vektor-verpackungsplasmide zur helfervirus-freien herstellung von wtaav-partikeln oder pseudotypisierten aav-partikeln über einzeltransfektion
WO2024097439A1 (en) Methods of treating human x-linked retinoschisis using gene therapy
EP1845163A2 (en) Adeno-associated virus serotype l nucleic acid sequences, vetors and host cells containing same
DE69636456T2 (de) In-vitro verpackung von adeno-assoziierten virus dns
Cooper et al. 131. Recombinant Adeno-Associated Virus 2-Mediated Transfer of the Human Superoxide-Dismutase Gene Does Not Confer Radioresistance on HeLa Cervical Carcinoma Cells
NZ753155B2 (en) Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8131 Rejection